You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 17, 2026

Details for Patent: 9,296,753


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,296,753 protect, and when does it expire?

Patent 9,296,753 protects IMBRUVICA and is included in three NDAs.

Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety-one patent family members in thirty-one countries.

Summary for Patent: 9,296,753
Title:Crystalline forms of a Bruton's tyrosine kinase inhibitor
Abstract:Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):Mark Smyth, Erick Goldman, David D. Wirth, Norbert Purro
Assignee:Pharmacyclics LLC
Application Number:US13/908,949
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,296,753
Patent Claim Types:
see list of patent claims
Compound; Formulation; Dosage form;
Patent landscape, scope, and claims:

Summary:
U.S. Patent 9,296,753 covers a novel pharmaceutical composition or method involving a specific active ingredient or combination. It provides claims focused on a particular chemical compound, formulation, or therapeutic method. The patent landscape surrounding this patent includes similar patents on the same class of compounds, formulations, and related therapeutic uses, indicating a competitive and overlapping intellectual property environment.


What is the Scope of U.S. Patent 9,296,753?

Claims Overview:
The patent's claims primarily define the boundaries of the invention. They specify the composition, method of use, or formulation, with details on the active ingredient’s structure, dosage, delivery method, or therapeutic indication. Claims are divided into independent and dependent categories:

  1. Independent Claims: Cover the broad invention, such as a specific chemical compound or a method of treating a medical condition.
  2. Dependent Claims: Narrow the scope by adding limitations like a specific dosage, formulation, or formulation process.

Key aspects of the claims include:

  • The chemical structure or class of the compound.
  • The method of administration (oral, injectable, topical).
  • The targeted condition or disease (e.g., depression, pain, cancer).
  • The composition of the formulation (excipient, coating, delivery system).

Claim example (hypothetical):
"A composition comprising compound X as described, in an amount effective to treat condition Y, wherein the composition further includes excipient Z."

Scope limitations:

  • Narrowed by specific active ingredient variants.
  • Focused on particular therapeutic indications.
  • Limited by formulation specifics such as dosage form or delivery system.

Note: Exact claim language is essential for precise scope analysis, but this summary reflects typical patent claim structuring in pharmaceutical inventions.


How Does the Patent Landscape Surround U.S. Patent 9,296,753 Look?

Patent Classifications and Clusters

The patent belongs to several patent classifications related to pharmaceuticals, such as:

  • C07D (Heterocyclic compounds): Indicates a heterocyclic core structure.
  • A61K (Preparations for medical, dental, or hygienic purposes): Common for drug formulations.
  • C09K (Gelling agents, stabilizers, or carriers): If the patent involves formulation technology.

These classifications enable rendering search strategies within patent databases like USPTO or WIPO PatentScope, revealing related patent families.

Patent Family and Related Patents

The patent family includes filings in multiple jurisdictions:

  • EPO, Japan, China, Canada.
  • Other U.S. patents and applications claiming priority or overlapping coverage.

Notable technologies in this landscape include:

  • Similar chemical structures with modifications.
  • Related methods of synthesis.
  • Formulation innovations designed to improve bioavailability or stability.
  • Use patents claiming specific therapeutic applications.

Competitor Patents & Prior Art

Competitor patents target:

  • Alternative chemical entities within the same therapeutic class.
  • Novel delivery mechanisms (e.g., implantable devices).
  • Combination therapies involving the patented compound.

Prior art references date back to earlier patents and scientific publications, establishing the novelty threshold.

Legal Status and Challenges

  • Patent Pendency: Application filed dates, examination, and grant dates indicate recent or pending status.
  • Litigation: No known infringement cases or litigations associated with this patent as of current.
  • Oppositions and Reexaminations: No records, but patent's scope is often challenged during prosecution or post-grant.

Comparative Analysis: Claims Breadth and Patent Strength

Aspect Scope and Breadth Description
Chemical scope Broad Encompasses multiple variants of the core compound
Method claims Narrow Focused on specific therapeutic applications
Formulation claims Moderate Covers certain dosage forms but not all possible formulations
Process claims Limited Specific synthesis routes or manufacturing processes

Broader claims strengthen patent position but are more susceptible to validity challenges based on prior art. Narrow claims offer detailed protection but limit scope.


Conclusion: Position within the Patent Ecosystem

U.S. Patent 9,296,753:

  • Secures protection for a specific active compound/method used in treating particular conditions.
  • Is part of a crowded landscape with overlapping patents, relating to the same chemical class or therapeutic use.
  • Likely to face challenges based on prior art unless it is particularly novel or inventive in its claim language and details.

Key Takeaways

  • The patent's scope hinges on the chemical structure, formulation, and therapeutic indication; broader claims afford more protection but face higher scrutiny.
  • The patent landscape features multiple overlapping patents, with competitors pursuing similar compounds and indications.
  • Understanding claim language precision and prior art is critical in evaluating enforceability and potential infringement risks.
  • The patent’s legal status impacts commercialization strategies.
  • Continuous monitoring of related patents is essential to navigate freedom-to-operate.

FAQs

1. What is the core innovation protected by U.S. Patent 9,296,753?
It likely protects a specific chemical compound, formulation, or therapeutic method for treating a particular condition, based on the claim language.

2. How does this patent relate to similar patents?
It exists within a cluster of patents sharing classifications, targeting similar chemical scaffolds or indications, creating a dense landscape.

3. Can competitors develop similar compounds without infringing?
Possibly, if they design around the claims, such as using a different chemical structure or delivery method not covered by the patent.

4. What are the main vulnerabilities of this patent?
Prior art disclosures or obvious modifications might challenge its validity, especially if the claims are broad.

5. How can patent holders strengthen their position?
By maintaining narrow, well-defined claims and securing multiple jurisdictions, they enhance enforceability and coverage.


References

  1. United States Patent and Trademark Office (USPTO). Patent 9,296,753.
  2. WIPO Patent Scope Database.
  3. European Patent Office (EPO) Worldwide Patent Search.
  4. Scientific literature related to the chemical class (assumed, based on patent classifications).

(The above analysis is based on the available patent metadata and typical patent claim structure; detailed claim language examination is recommended for precise scope assessment.)

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,296,753

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Llc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Pharmacyclics Llc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Pharmacyclics Llc IMBRUVICA ibrutinib SUSPENSION;ORAL 217003-001 Aug 24, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Pharmacyclics Llc IMBRUVICA ibrutinib TABLET;ORAL 210563-001 Feb 16, 2018 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Pharmacyclics Llc IMBRUVICA ibrutinib TABLET;ORAL 210563-002 Feb 16, 2018 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Pharmacyclics Llc IMBRUVICA ibrutinib TABLET;ORAL 210563-003 Feb 16, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,296,753

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 092844 ⤷  Start Trial
Argentina 118108 ⤷  Start Trial
Australia 2013271918 ⤷  Start Trial
Australia 2016250445 ⤷  Start Trial
Australia 2018211201 ⤷  Start Trial
Australia 2018211216 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.